Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival rate of 13.3%. First-line treatment relies on two chemotherapy regimens, FOLFIRINOX (FOLFNX) or gemcitabine plus nab-paclitaxel (GEMPAC). However, direct clinical comparisons between these regimens have yielde...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Amirsalar Mansouri, Olivia Hart, Sina Aslanabadi, Conner Hartupee, Dicle Yalcin, Garima Sinha, Chiswili Yves Chabu, Aleksandra Cios, Zetao Cheng, Sudhakar Ammanamanchi, Jovanny Zabaleta, John H. Stewart, John T. West, Mitesh J. Borad, Bolni Marius Nagalo, Jiri Adamec, Omeed Moaven
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	MDPI AG 2026-03-01
श्रृंखला:	Cells
विषय:	PDAC MIA PaCa2 FOLFIRINOX gemcitabine chemotherapy proteomics
ऑनलाइन पहुंच:	https://www.mdpi.com/2073-4409/15/6/531
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!